Goldman Sachs
OTLK icon

Goldman Sachs’s Outlook Therapeutics OTLK Stock Holding History

Goldman Sachs’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.12K Sell
10,275
-35,507
-78% -$15.3K ﹤0.01% 6419
2025
Q4 		$72.3K Buy
45,782
+2,812
+7% +$4.49K ﹤0.01% 6245
2025
Q3 		$45.5K Sell
42,970
-49,398
-53% -$85.4K ﹤0.01% 6181
2025
Q2 		$148K Sell
92,368
-11,156
-11% -$17.8K ﹤0.01% 5741
2025
Q1 		$126K Buy
103,524
+44,063
+74% +$77.3K ﹤0.01% 5738
2024
Q4 		$112K Buy
59,461
+23,887
+67% +$98.3K ﹤0.01% 5745
2024
Q3 		$190K Buy
+35,574
New +$260K ﹤0.01% 5472
2024
Q1 		– Sell
-2,767
Closed -$21.8K – 5789
2023
Q4 		$21.8K Sell
2,767
-295
-10% -$2.49K ﹤0.01% 5440
2023
Q3 		$13.5K Sell
3,062
-3,569
-54% -$79K ﹤0.01% 5386
2023
Q2 		$231K Buy
6,631
+3,080
+87% +$84K ﹤0.01% 5126
2023
Q1 		$77.4K Sell
3,551
-5,826
-62% -$130K ﹤0.01% 5491
2022
Q4 		$203K Buy
9,377
+4,643
+98% +$101K ﹤0.01% 5302
2022
Q3 		$115K Sell
4,734
-529
-10% -$12.3K ﹤0.01% 5653
2022
Q2 		$107K Sell
5,263
-1,643
-24% -$47.2K ﹤0.01% 5840
2022
Q1 		$246K Buy
6,906
+1,340
+24% +$41.8K ﹤0.01% 5769
2021
Q4 		$152K Sell
5,566
-1,990
-26% -$71K ﹤0.01% 6002
2021
Q3 		$328K Buy
7,556
+7,027
+1,328% +$339K ﹤0.01% 5441
2021
Q2 		$26K Sell
529
-3,785
-88% -$176K ﹤0.01% 6130
2021
Q1 		$194K Buy
4,314
+2,023
+88% +$77.5K ﹤0.01% 5659
2020
Q4 		$60K Sell
2,291
-1,575
-41% -$32.9K ﹤0.01% 5357
2020
Q3 		$56K Buy
+3,866
New +$86.2K ﹤0.01% 5174
2017
Q1 		– Sell
-811
Closed -$390K – 6932
2016
Q4 		$390K Sell
811
-6
-0.7% -$3.36K ﹤0.01% 5274
2016
Q3 		$555K Buy
+817
New +$519K ﹤0.01% 4944

Other funds holding OTLK

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $126M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
Nine Masts Capital Central, Hong Kong $693M AUM 31.93% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Goldman Sachs's OTLK Position: Q1 2026 in Review

Goldman Sachs reduced its Outlook Therapeutics (OTLK) stake by 78% in Q1 2026, selling an estimated $15.3K and leaving 10,275 shares worth $2.12K. The position accounts for ﹤0.01% of the portfolio, ranked #6419.

Goldman Sachs first reported a position in OTLK in Q3 2016 and has held it in 23 quarters since. The position peaked at $555K in Q3 2016. 54 funds tracked by Wall St. Rank hold OTLK as of Q1 2026.

  • Goldman Sachs held 10,275 shares of Outlook Therapeutics worth $2.12K as of Q1 2026.
  • Goldman Sachs sold 35,507 Outlook Therapeutics shares in Q1 2026, an estimated $15.3K.
  • Outlook Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6419 holding.
  • Goldman Sachs first reported a position in Outlook Therapeutics in Q3 2016 and has held it in 23 quarters since.
  • Goldman Sachs's Outlook Therapeutics position peaked at $555K in Q3 2016.
  • 54 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.